uniQure (QURE)
Market Price (5/11/2026): $28.3 | Market Cap: $1.8 BilSector: Health Care | Industry: Biotechnology
uniQure (QURE)
Market Price (5/11/2026): $28.3Market Cap: $1.8 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -30% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. | Weak multi-year price returns3Y Excs Rtn is -47% Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 18% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -188 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1040% Expensive valuation multiplesP/SPrice/Sales ratio is 96x Stock price has recently run up significantly12M Rtn12 month market price return is 116% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -10%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -29% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 101% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -951%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -954% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -16% High stock price volatilityVol 12M is 273% Key risksQURE key risks include [1] an uncertain regulatory pathway for its lead Huntington's disease therapy, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -30% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. |
| Weak multi-year price returns3Y Excs Rtn is -47% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 18% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -188 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1040% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 96x |
| Stock price has recently run up significantly12M Rtn12 month market price return is 116% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -10%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -29% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 101% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -951%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -954% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -16% |
| High stock price volatilityVol 12M is 273% |
| Key risksQURE key risks include [1] an uncertain regulatory pathway for its lead Huntington's disease therapy, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Positive Regulatory and Clinical Momentum for Huntington's Disease Program (AMT-130).
uniQure experienced a significant boost from progress in the regulatory pathway for its lead gene therapy candidate, AMT-130, for Huntington's disease. In April 2026, a pre-submission meeting with the UK's Medicines and Healthcare products Regulatory Agency (MHRA) was successfully concluded, paving the way for a planned Marketing Authorization Application (MAA) in the third quarter of 2026. This application will be supported by compelling three-year Phase I/II data demonstrating a statistically significant 75% slowing of disease progression at the high dose with a manageable safety profile. Additionally, a Type B meeting with the U.S. FDA is scheduled for the second quarter of 2026 to discuss a new trial design and statistical plan, providing a clear path forward despite earlier FDA feedback.
2. Encouraging Clinical Data for Fabry Disease Program (AMT-191).
Further contributing to investor optimism were the updated Phase I/II clinical data for AMT-191 in Fabry disease, presented in February 2026. The data showed dose-dependent and durable increases in α-Gal A enzyme activity, a key biomarker for Fabry disease. Notably, all 11 dosed patients in the study had successfully discontinued enzyme replacement therapy as of February 18, 2026, indicating a promising therapeutic effect and potential for a significant treatment advance.
Show more
Stock Movement Drivers
Fundamental Drivers
The 21.7% change in QURE stock from 1/31/2026 to 5/10/2026 was primarily driven by a 14.9% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312026 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 22.72 | 27.66 | 21.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 16 | 18 | 14.9% |
| P/S Multiple | 84.4 | 95.9 | 13.6% |
| Shares Outstanding (Mil) | 59 | 63 | -6.7% |
| Cumulative Contribution | 21.7% |
Market Drivers
1/31/2026 to 5/10/2026| Return | Correlation | |
|---|---|---|
| QURE | 21.7% | |
| Market (SPY) | 3.6% | 16.8% |
| Sector (XLV) | -6.9% | 15.6% |
Fundamental Drivers
The -59.1% change in QURE stock from 10/31/2025 to 5/10/2026 was primarily driven by a -62.9% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 67.69 | 27.66 | -59.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 14 | 18 | 26.2% |
| P/S Multiple | 258.8 | 95.9 | -62.9% |
| Shares Outstanding (Mil) | 55 | 63 | -12.6% |
| Cumulative Contribution | -59.1% |
Market Drivers
10/31/2025 to 5/10/2026| Return | Correlation | |
|---|---|---|
| QURE | -59.1% | |
| Market (SPY) | 5.5% | 9.1% |
| Sector (XLV) | 0.3% | 11.8% |
Fundamental Drivers
The 87.4% change in QURE stock from 4/30/2025 to 5/10/2026 was primarily driven by a 260.6% change in the company's P/S Multiple.| (LTM values as of) | 4302025 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 14.76 | 27.66 | 87.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 27 | 18 | -33.3% |
| P/S Multiple | 26.6 | 95.9 | 260.6% |
| Shares Outstanding (Mil) | 49 | 63 | -22.1% |
| Cumulative Contribution | 87.4% |
Market Drivers
4/30/2025 to 5/10/2026| Return | Correlation | |
|---|---|---|
| QURE | 87.4% | |
| Market (SPY) | 30.4% | 2.4% |
| Sector (XLV) | 4.0% | 3.5% |
Fundamental Drivers
The 42.5% change in QURE stock from 4/30/2023 to 5/10/2026 was primarily driven by a 1022.0% change in the company's P/S Multiple.| (LTM values as of) | 4302023 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 19.41 | 27.66 | 42.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 106 | 18 | -83.0% |
| P/S Multiple | 8.5 | 95.9 | 1022.0% |
| Shares Outstanding (Mil) | 47 | 63 | -25.3% |
| Cumulative Contribution | 42.5% |
Market Drivers
4/30/2023 to 5/10/2026| Return | Correlation | |
|---|---|---|
| QURE | 42.5% | |
| Market (SPY) | 78.7% | 10.2% |
| Sector (XLV) | 13.0% | 7.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| QURE Return | -43% | 9% | -70% | 161% | 36% | 1% | -33% |
| Peers Return | -26% | 17% | 4% | -19% | 27% | -10% | -16% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 95% |
Monthly Win Rates [3] | |||||||
| QURE Win Rate | 25% | 33% | 8% | 50% | 33% | 60% | |
| Peers Win Rate | 43% | 62% | 48% | 42% | 60% | 36% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| QURE Max Drawdown | -44% | -37% | -75% | -44% | -53% | -62% | |
| Peers Max Drawdown | -39% | -18% | -26% | -27% | -36% | -20% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: BMRN, SRPT, IONS, VRTX, RGNX. See QURE Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/8/2026 (YTD)
How Low Can It Go
| Event | QURE | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -37.8% | -18.8% |
| % Gain to Breakeven | 60.8% | 23.1% |
| Time to Breakeven | 14 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -35.1% | -7.8% |
| % Gain to Breakeven | 54.0% | 8.5% |
| Time to Breakeven | 113 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -40.8% | -9.5% |
| % Gain to Breakeven | 68.9% | 10.5% |
| Time to Breakeven | 257 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -47.9% | -6.7% |
| % Gain to Breakeven | 92.1% | 7.1% |
| Time to Breakeven | 818 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -38.8% | -24.5% |
| % Gain to Breakeven | 63.5% | 32.4% |
| Time to Breakeven | 57 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -38.3% | -33.7% |
| % Gain to Breakeven | 62.2% | 50.9% |
| Time to Breakeven | 76 days | 140 days |
In The Past
uniQure's stock fell -37.8% during the 2025 US Tariff Shock. Such a loss loss requires a 60.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | QURE | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -37.8% | -18.8% |
| % Gain to Breakeven | 60.8% | 23.1% |
| Time to Breakeven | 14 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -35.1% | -7.8% |
| % Gain to Breakeven | 54.0% | 8.5% |
| Time to Breakeven | 113 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -40.8% | -9.5% |
| % Gain to Breakeven | 68.9% | 10.5% |
| Time to Breakeven | 257 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -47.9% | -6.7% |
| % Gain to Breakeven | 92.1% | 7.1% |
| Time to Breakeven | 818 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -38.8% | -24.5% |
| % Gain to Breakeven | 63.5% | 32.4% |
| Time to Breakeven | 57 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -38.3% | -33.7% |
| % Gain to Breakeven | 62.2% | 50.9% |
| Time to Breakeven | 76 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -31.1% | -19.2% |
| % Gain to Breakeven | 45.1% | 23.7% |
| Time to Breakeven | 78 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -42.0% | -3.7% |
| % Gain to Breakeven | 72.4% | 3.9% |
| Time to Breakeven | 76 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -60.7% | -12.2% |
| % Gain to Breakeven | 154.2% | 13.9% |
| Time to Breakeven | 755 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -20.8% | -6.8% |
| % Gain to Breakeven | 26.2% | 7.3% |
| Time to Breakeven | 27 days | 15 days |
| 2013 Taper Tantrum | ||
| % Loss | -39.1% | -0.2% |
| % Gain to Breakeven | 64.2% | 0.2% |
| Time to Breakeven | 219 days | 1 days |
In The Past
uniQure's stock fell -37.8% during the 2025 US Tariff Shock. Such a loss loss requires a 60.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About uniQure (QURE)
AI Analysis | Feedback
Analogy 1: Imagine **Moderna**, but instead of mRNA technology, uniQure focuses on developing groundbreaking gene therapies for genetic diseases.
Analogy 2: A **Vertex Pharmaceuticals** dedicated to creating gene therapies for severe genetic conditions like hemophilia and Huntington's disease.
AI Analysis | Feedback
- Etranacogene dezaparvovec (AMT-061): A gene therapy in Phase III clinical trial for the treatment of hemophilia B.
- AMT-130: A gene therapy in Phase I/II clinical study for the treatment of Huntington's disease.
- AMT-060: A gene therapy in Phase I/II clinical trial for the treatment of hemophilia B.
- AMT-210: A product candidate for the treatment of Parkinson's disease.
- AMT-260: A product candidate for the treatment of temporal lobe epilepsy.
- AMT-240: A preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease.
- AMT-161: A product candidate for the treatment of amyotrophic lateral sclerosis.
AI Analysis | Feedback
uniQure N.V. (QURE) is a gene therapy company primarily engaged in the research and development of treatments for genetic and other devastating diseases. As a biopharmaceutical company with most of its pipeline in clinical development stages, uniQure does not typically sell directly to individual patients. Instead, its "customers" or key partners for commercialized products are other pharmaceutical companies or healthcare systems. For its lead program, Etranacogene dezaparvovec (AMT-061), which is now marketed under the brand name HEMGENIX® for hemophilia B, uniQure has licensed the global commercialization rights. Therefore, its major customer/partner for this commercialized product is: * **CSL Behring**, a subsidiary of **CSL Limited** (ASX: CSL). CSL Behring holds the exclusive global license for the commercialization of HEMGENIX®. For its other pipeline product candidates, such as AMT-130 for Huntington's disease, AMT-210 for Parkinson's disease, and others, these are still in various stages of clinical trials or preclinical development. Consequently, uniQure currently does not have commercial customers for these investigational therapies. If these programs are successfully developed and approved, uniQure may commercialize them independently, partner with other pharmaceutical companies, or license them out, similar to the arrangement for HEMGENIX®.AI Analysis | Feedback
- Bristol Myers Squibb Company (BMY)
- Catalent, Inc. (CTLT)
- Lonza Group Ltd (LONN)
AI Analysis | Feedback
Matt Kapusta, Chief Executive Officer
Matt Kapusta has served as Chief Executive Officer of uniQure since December 2016 and is also an Executive Director on the Board. He previously held the role of Chief Financial Officer for uniQure from January 2015 until June 2021. Prior to joining uniQure, Mr. Kapusta held executive positions at AngioDynamics from 2011 to 2015 and Smith & Nephew from 2009 to 2011. His career also includes more than a decade of investment banking experience focused on emerging life-sciences companies, including serving as Managing Director, Healthcare Investment Banking at Collins Stewart, and various roles at Wells Fargo Securities, Robertson Stephens, and PaineWebber.
Christian Klemt, Chief Financial Officer
Christian Klemt was appointed Chief Financial Officer of uniQure in June 2021. Prior to this role, he served as uniQure's Chief Accounting Officer from August 2017 to June 2021. Mr. Klemt also continues to serve as the General Manager of uniQure's Amsterdam site.
Walid Abi-Saab, M.D., Chief Medical Officer
Walid Abi-Saab joined uniQure as Chief Medical Officer in June 2023. In this role, he is responsible for leading clinical research and development, regulatory affairs, medical affairs, and program management. Before uniQure, Dr. Abi-Saab served as Chief Medical Officer at Galapagos from 2017 through 2022, where he expanded the company's development organization and led the successful completion of Phase 3 studies for filgotinib. He has also held leadership positions at companies such as Novartis, Abbott Laboratories, Pfizer, and served as Group Vice President, Global Clinical Development at Shire.
Richard Porter, Ph.D., Chief Business and Scientific Officer
Richard Porter assumed responsibilities for research, non-clinical, and vector development in his role as Chief Business and Scientific Officer following a strategic reorganization in October 2023. He also continues to oversee business development and product planning. Dr. Porter joined uniQure in June 2021 through the acquisition of Corlieve Therapeutics, where he was the founder and Chief Executive Officer. He possesses over 25 years of neuroscience leadership experience in the biopharma industry.
Kylie O'Keefe, Chief Customer and Strategy Officer
Kylie O'Keefe was appointed Chief Customer and Strategy Officer in June 2025, where she is responsible for leading the development and execution of uniQure's global commercialization strategy for AMT-130, including all commercial functions and medical affairs. Prior to joining uniQure, Ms. O'Keefe served as Chief Commercial Officer at PTC Therapeutics, overseeing global commercial strategy, operations, and portfolio management for multiple rare neurology and metabolic commercial products across more than 50 countries. Her experience includes leading several strategically significant commercial launches and supporting corporate strategy and pipeline development for both small molecules and gene therapies.
AI Analysis | Feedback
uniQure (NASDAQ: QURE) faces several significant business risks, primarily stemming from the challenging regulatory landscape and the inherent uncertainties of gene therapy development. The most prominent risk centers on **regulatory and legal challenges for its Huntington's disease gene therapy candidate, AMT-130**. The U.S. Food and Drug Administration (FDA) has "strongly recommended" that uniQure conduct a new, costly, and lengthy Phase III sham-controlled study for AMT-130, rejecting the company's current data package for accelerated approval. This decision significantly alters the drug's path to market, increasing both development risks and capital requirements. Further exacerbating this risk, an unnamed senior FDA official has publicly criticized uniQure, accusing the company of presenting "distorted" and "manipulated" clinical data for a "failed" therapy and of misleading behavior in its interactions with federal health authorities. These accusations have led to a substantial drop in uniQure's share price and have prompted multiple law firms to file securities fraud class-action lawsuits against the company, alleging misleading statements about FDA alignment and timelines for AMT-130. Such legal actions expose uniQure to significant financial penalties and reputational damage. A second key risk arises from the **inherent complexities and uncertainties of gene therapy development**. Developing gene therapies is a costly endeavor with a high risk of clinical trial failure. While uniQure has programs in various clinical phases, there are ongoing concerns regarding long-term safety, including potential delayed adverse effects, immune responses, and unintended off-target effects. Manufacturing these advanced therapeutic medicinal products also presents significant challenges related to quality control, scalability, and standardization. Even if a therapy gains regulatory approval, commercialization hurdles such as high treatment costs and challenges in market acceptance and reimbursement pose additional risks. Finally, uniQure's **financial health and cash burn** present a significant business risk. The company has experienced a substantial revenue growth decline and a deeply negative net margin over the past three years. Although uniQure currently holds a strong cash position, its considerable annual cash burn rate, estimated at nearly $200 million, means that the newly recommended, extended Phase III trial for AMT-130 will severely test its financial resilience. The company's Altman Z-Score, which indicates financial distress, is also low, implying a potential risk of bankruptcy in the near future.AI Analysis | Feedback
nullAI Analysis | Feedback
uniQure N.V. (symbol: QURE) operates in the gene therapy space, developing treatments for genetic and other devastating diseases. The addressable markets for their main products are as follows:
Etranacogene dezaparvovec (HEMGENIX) for Hemophilia B
HEMGENIX (etranacogene dezaparvovec) is uniQure's approved gene therapy for hemophilia B. The global market for hemophilia B gene therapy was valued at approximately USD 0.51 billion in 2023 and is projected to reach USD 3.43 billion by 2032, growing at a compound annual growth rate (CAGR) of roughly 23.60% between 2024 and 2032. The broader global hemophilia B market was valued at US$ 2,956.0 million in 2024 and is estimated to grow to US$ 4,362.0 million by 2030. In the United States, the hemophilia B market size was approximately USD 2 billion in 2023.
AMT-130 for Huntington's Disease
Huntington's disease impacts approximately 75,000 people across the U.S., Europe, and the UK. The global Huntington's disease treatment market was valued at USD 1.2 billion in 2024 and is projected to reach USD 3.7 billion by 2034, exhibiting an 8.9% CAGR. Another estimate places the global market at USD 578.9 million in 2024, expected to reach USD 2,443 million by 2033 with a CAGR of 17.4% from 2025-2033. The North American market for Huntington's disease treatment held the leading regional position in 2024, with an estimated value of approximately USD 0.5 billion.
AMT-210 for Parkinson's Disease
uniQure announced in October 2023 its decision to discontinue the AMT-210 program for Parkinson's disease as part of a strategic reorganization. Therefore, there is no addressable market size for this specific product from uniQure's portfolio.
AI Analysis | Feedback
uniQure N.V. (QURE) is expected to drive future revenue growth over the next 2-3 years primarily through the commercialization of its gene therapies. The key drivers include:- Commercialization and Market Penetration of Hemgenix (etranacogene dezaparvovec): uniQure's approved gene therapy for hemophilia B, Hemgenix, is a current source of revenue, and its continued rollout and increasing adoption in the market are anticipated to contribute to revenue growth.
- Potential Regulatory Approval and Commercial Launch of AMT-130 for Huntington's Disease: Despite recent regulatory setbacks and the U.S. FDA recommending a Phase III sham-controlled study, AMT-130 remains a significant potential revenue driver. Analysts project substantial annual revenue if approved, with a potential commercial launch in 2027 or 2028.
- Expansion into International Markets: The company is actively engaging with regulatory authorities outside the U.S. for its pipeline assets, including AMT-130. This strategic focus on international markets presents an opportunity for geographical expansion and increased revenue from existing or newly approved products.
AI Analysis | Feedback
Share Issuance
- In 2025, uniQure received aggregate net proceeds of $404.2 million from follow-on public offerings, which included the issuance of 11.8 million ordinary shares and pre-funded warrants to purchase 0.5 million ordinary shares.
- An underwritten public offering in September 2025 generated approximately $345 million in gross proceeds from the sale of 6,736,841 ordinary shares and 526,316 pre-funded warrants.
- Net proceeds of $80.5 million were raised in January and February 2025 through a follow-on offering.
Inbound Investments
- uniQure refinanced its existing $50 million debt in the third quarter of 2025, extending the term to October 2030 and reducing its cost of capital.
- An additional term loan tranche of $100 million is available, subject to a pre-defined regulatory milestone for AMT-130, with a third tranche of $25 million also available upon lender approval.
- The company's cash and investments grew to $622.5 million as of December 31, 2025, primarily due to proceeds from public offerings, up from $367.5 million at the end of 2024.
Capital Expenditures
- Research and development expenses totaled $140.7 million in 2025, a decrease from $143.8 million in 2024.
- Selling, general and administrative expenses were $65.5 million in 2025, increasing from $52.7 million in 2024, partly due to $6.5 million incurred for the planned commercialization of AMT-130 in the United States.
- In the third quarter of 2025, direct research and development expenses increased by $10.1 million, including $6.6 million related to the preparation for the Biologics License Application submission for AMT-130.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| uniQure Stock Pre-Market (+51%): FDA Clarifies Trial Path, Igniting Squeeze | 03/07/2026 | |
| Would You Still Hold uniQure Stock If It Fell Another 30%? | 10/17/2025 | |
| uniQure (QURE) Operating Cash Flow Comparison | 09/25/2025 | |
| uniQure (QURE) Operating Income Comparison | 09/25/2025 | |
| uniQure (QURE) Net Income Comparison | 09/25/2025 | |
| uniQure (QURE) Debt Comparison | 09/25/2025 | |
| uniQure (QURE) Tax Expense Comparison | 09/25/2025 | |
| uniQure (QURE) Revenue Comparison | 09/25/2025 | |
| uniQure (QURE) EBITDA Comparison | 09/25/2025 | |
| QURE Dip Buy Analysis | 07/10/2025 | |
| ARTICLES | ||
| Market Movers | Winners: ADTX, CJET, ABP | Losers: DD, QURE, ZOOZ | 11/04/2025 | |
| UniQure’s Rally Is Just Getting Started | 09/25/2025 | |
| Market Movers | Winners: MNDR, QURE, SHFS | Losers: WOK, JZXN, INHD | 09/25/2025 | |
| What Led To A 150% Rise In uniQure Stock In A Week? | 07/11/2024 | |
| Up 43% In A Month, Will uniQure Stock See Further Gains? | 07/11/2022 |
Trade Ideas
Select ideas related to QURE.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 40.86 |
| Mkt Cap | 6.3 |
| Rev LTM | 1,621 |
| Op Inc LTM | -80 |
| FCF LTM | -9 |
| FCF 3Y Avg | -169 |
| CFO LTM | 26 |
| CFO 3Y Avg | -164 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.0% |
| Rev Chg 3Y Avg | 19.6% |
| Rev Chg Q | 25.4% |
| QoQ Delta Rev Chg LTM | 3.7% |
| Op Inc Chg LTM | 27.9% |
| Op Inc Chg 3Y Avg | 33.9% |
| Op Mgn LTM | -16.6% |
| Op Mgn 3Y Avg | -26.9% |
| QoQ Delta Op Mgn LTM | 4.3% |
| CFO/Rev LTM | -32.4% |
| CFO/Rev 3Y Avg | -42.0% |
| FCF/Rev LTM | -34.6% |
| FCF/Rev 3Y Avg | -48.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 6.3 |
| P/S | 6.1 |
| P/Op Inc | 10.0 |
| P/EBIT | 9.0 |
| P/E | 11.2 |
| P/CFO | 3.7 |
| Total Yield | -0.0% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -6.2% |
| D/E | 0.1 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -0.1% |
| 3M Rtn | -2.4% |
| 6M Rtn | 4.0% |
| 12M Rtn | 20.7% |
| 3Y Rtn | -10.3% |
| 1M Excs Rtn | -10.8% |
| 3M Excs Rtn | -9.2% |
| 6M Excs Rtn | -6.1% |
| 12M Excs Rtn | -9.1% |
| 3Y Excs Rtn | -89.9% |
Price Behavior
| Market Price | $27.66 | |
| Market Cap ($ Bil) | 1.7 | |
| First Trading Date | 02/05/2014 | |
| Distance from 52W High | -60.8% | |
| 50 Days | 200 Days | |
| DMA Price | $16.84 | $25.67 |
| DMA Trend | up | down |
| Distance from DMA | 64.3% | 7.8% |
| 3M | 1YR | |
| Volatility | 163.7% | 274.6% |
| Downside Capture | 0.41 | -0.76 |
| Upside Capture | 99.88 | -10.42 |
| Correlation (SPY) | 16.1% | 1.7% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.31 | 1.15 | 1.81 | 1.01 | 0.51 | 1.28 |
| Up Beta | 1.11 | 3.61 | 3.26 | 3.92 | 2.41 | 1.32 |
| Down Beta | 0.07 | -1.26 | -1.17 | -0.40 | 2.40 | 2.01 |
| Up Capture | 215% | 98% | 151% | -94% | 3% | 105% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 13 | 22 | 32 | 56 | 121 | 342 |
| Down Capture | 584% | 33% | 237% | 163% | -53% | 107% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 9 | 21 | 32 | 69 | 130 | 400 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with QURE | |
|---|---|---|---|---|
| QURE | 175.5% | 274.3% | 1.08 | - |
| Sector ETF (XLV) | 7.9% | 15.4% | 0.30 | 2.2% |
| Equity (SPY) | 29.0% | 12.5% | 1.83 | 1.9% |
| Gold (GLD) | 39.8% | 27.0% | 1.22 | -1.7% |
| Commodities (DBC) | 50.6% | 18.0% | 2.21 | 3.2% |
| Real Estate (VNQ) | 13.0% | 13.5% | 0.66 | -6.9% |
| Bitcoin (BTCUSD) | -17.4% | 42.1% | -0.34 | 4.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with QURE | |
|---|---|---|---|---|
| QURE | -3.7% | 153.7% | 0.45 | - |
| Sector ETF (XLV) | 4.9% | 14.6% | 0.16 | 11.4% |
| Equity (SPY) | 12.8% | 17.1% | 0.59 | 15.2% |
| Gold (GLD) | 20.9% | 17.9% | 0.95 | 0.6% |
| Commodities (DBC) | 13.8% | 19.1% | 0.59 | 1.0% |
| Real Estate (VNQ) | 3.4% | 18.8% | 0.08 | 8.8% |
| Bitcoin (BTCUSD) | 7.0% | 56.0% | 0.34 | 8.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with QURE | |
|---|---|---|---|---|
| QURE | 7.9% | 119.8% | 0.46 | - |
| Sector ETF (XLV) | 9.3% | 16.5% | 0.46 | 16.3% |
| Equity (SPY) | 15.1% | 17.9% | 0.72 | 18.1% |
| Gold (GLD) | 13.4% | 15.9% | 0.69 | 1.2% |
| Commodities (DBC) | 9.3% | 17.8% | 0.44 | 3.7% |
| Real Estate (VNQ) | 5.8% | 20.7% | 0.24 | 10.4% |
| Bitcoin (BTCUSD) | 67.8% | 66.9% | 1.07 | 7.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/2/2026 | -32.8% | -8.7% | -5.8% |
| 11/10/2025 | -5.9% | 7.5% | -27.5% |
| 7/29/2025 | -8.7% | -8.1% | 5.4% |
| 5/9/2025 | 4.4% | 8.2% | 38.0% |
| 2/27/2025 | 3.4% | 3.6% | 12.5% |
| 11/5/2024 | 9.0% | 37.8% | 13.1% |
| 8/1/2024 | -2.3% | -7.0% | -18.8% |
| 2/28/2024 | -0.9% | -25.3% | -19.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 8 | 10 |
| # Negative | 10 | 13 | 11 |
| Median Positive | 3.6% | 7.7% | 13.2% |
| Median Negative | -4.3% | -8.3% | -17.8% |
| Max Positive | 12.7% | 37.8% | 38.0% |
| Max Negative | -32.8% | -25.3% | -27.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 03/02/2026 | 10-K |
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 07/29/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/05/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/01/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/27/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| 06/30/2022 | 08/08/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q1 2026 Earnings Reported 5/5/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2029 Cash Runway | 2,030 | ||||||
Prior: Q4 2025 Earnings Reported 3/2/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2029 Cash Runway | Affirmed | Guidance: 2,029 for 2029 | |||||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kapusta, Matthew C | CEO, Managing Director | Direct | Sell | 3062026 | 9.06 | 14,581 | 132,104 | 5,985,561 | Form |
| 2 | Abi-Saab, Walid | Chief Medical Officer | Direct | Sell | 3062026 | 9.06 | 808 | 7,320 | 1,718,401 | Form |
| 3 | Potts, Jeannette | Chief Legal Officer | Direct | Sell | 3062026 | 9.06 | 3,412 | 30,913 | 1,254,656 | Form |
| 4 | Klemt, Christian | Chief Financial Officer | Direct | Sell | 3062026 | 9.06 | 12,000 | 108,720 | 2,052,824 | Form |
| 5 | Kapusta, Matthew C | CEO, Managing Director | Direct | Sell | 3042026 | 9.95 | 34,437 | 342,648 | 6,016,158 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.